Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

15-Year Follow-up of Protection and Immunity After Bivalent HPV Vaccination in Women (HPV Vaccine)

14 de noviembre de 2026 actualizado por: Jun Zhang, Xiamen University

A 15-Year Follow-up Study of Long-Term Protection and Immunopersistence of an Escherichia Coli-Produced Bivalent HPV-16/18 Vaccine in Healthy Women Aged 18-45 Years

This study aims to evaluate the long-term protection provided by a bivalent HPV vaccine produced in Escherichia coli against specific clinical endpoints related to HPV types 16 and 18 in women aged 18-45 years, as well as the persistence of antibodies specific to these two HPV types.

Descripción general del estudio

Descripción detallada

This observational study is a long-term follow-up of participants in the phase III clinical trial of a bivalent HPV 16/18 vaccine produced in Escherichia coli (HPV-PRO-003, NCT01735006). Women aged 18-45 years at enrollment in the original trial were randomly assigned to receive either the HPV vaccine or a hepatitis E vaccine. The follow-up study will retain the original vaccine and control groups. No additional study intervention will be administered.

Through 15 years after the first dose, this study aims to evaluate the long-term protection provided by the bivalent HPV vaccine against specific clinical endpoints associated with HPV types 16 and/or 18 and to assess the persistence of antibodies specific to HPV types 16 and 18.

Tipo de estudio

De observación

Inscripción (Estimado)

2000

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Ting Wu
  • Número de teléfono: 0592-2880621
  • Correo electrónico: wuting.@xmu.edu.cn

Ubicaciones de estudio

    • Guangxi
      • Liuzhou, Guangxi, Porcelana, 545007
        • Liuzhou Center for Disease Control and Prevention
        • Contacto:
          • Haibo Wang, MSc
          • Número de teléfono: +86-772-3720738
          • Correo electrónico: lzcdcxmb@163.com
    • Hebei
      • Fengning, Hebei, Porcelana, 068350
        • Fengning Hospital of Traditional Chinese Medicine
        • Contacto:
          • Cuihong Dai, BSc
          • Número de teléfono: +86-314-8080327
          • Correo electrónico: wxn_cdfn@126.com
    • Henan
      • Qingpingjie, Henan, Porcelana, 452370
        • Xinmi Maternal and Child Health Hospital
        • Contacto:
          • Fengxian Zheng, BSc
          • Número de teléfono: +86-371-69833851
          • Correo electrónico: 513940819@qq.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Femenino

Método de muestreo

Muestra no probabilística

Población de estudio

The study population comprises women who received at least one dose of their assigned vaccine in the original phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003). To be eligible, women must not have received any HPV vaccine outside their original trial assignment since enrollment in that trial, including any subsequent catch-up doses given to control group participants. Participants retain their original group assignments (HPV vaccine group or hepatitis E vaccine control group).

Descripción

Inclusion Criteria:

  • The participant took part in the phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003) and received at least one dose of the vaccine assigned to her in that trial.
  • The participant has given informed consent and signed the consent form.
  • The participant is able to complete all study procedures as required by the protocol.

Exclusion Criteria:

  • Since enrollment in the original phase III trial, the participant has received any HPV vaccine other than the study vaccination assigned under the original trial protocol. This includes subsequent catch-up vaccination with the investigational vaccine among participants in the original control group, as well as receipt of any other licensed or unlicensed HPV vaccine.
  • The participant had an invasive malignancy of the cervix, vagina, or vulva before enrollment in this follow-up study, or an abnormality detected at screening is confirmed to be an invasive malignancy at one of these sites by histopathological examination of a colposcopy-directed biopsy specimen.
  • In the investigator's judgment, a medical, psychological, social, occupational, or other circumstance would interfere with the participant's ability to comply with the protocol or to provide written informed consent.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Vaccine group

Women assigned to the vaccine group in the original phase III trial who received at least one dose of the bivalent HPV 16/18 vaccine. Since enrollment in the original trial, they must not have received any HPV vaccine other than the study vaccine administered as specified in that trial's protocol. Participants must also meet all other eligibility criteria for this follow-up study.

The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant

Control group

Women assigned to the control group in the original phase III trial who received at least one dose of control vaccine (hepatitis E vaccine). Since enrollment in the original trial, they must not have received any HPV vaccine other than vaccination specified in the original trial protocol. Participants must also meet all other eligibility criteria for this follow-up study.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
CIN2+, VIN2+, or VaIN2+ associated with HPV type 16 or 18 in the per-protocol population
Periodo de tiempo: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 2 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
6-month persistent infection with HPV type 16 or 18 in the per-protocol population
Periodo de tiempo: At months 156 and 180 after the first dose in the original trial

Infection with the same HPV type must persist for at least 6 months

At months 156 and 180 after the first dose in the original trial

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
CIN1+, VIN1+, or VaIN1+ associated with HPV type 16 or 18
Periodo de tiempo: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 1 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
CIN2+ associated with HPV type 16 or 18
Periodo de tiempo: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 2 or worse cervical intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
VIN2+, or VaIN2+ associated with HPV type 16 or 18
Periodo de tiempo: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 2 or worse vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
HPV-16-specific infection and/or lesion endpoints
Periodo de tiempo: At months 156 and 180 after the first dose in the original trial

6-month persistent infection and grade 2 or worse cervical intraepithelial

At months 156 and 180 after the first dose in the original trial
HPV-18-specific infection and/or lesion endpoints
Periodo de tiempo: At months 156 and 180 after the first dose in the original trial

6-month persistent infection and grade 2 or worse cervical intraepithelial

At months 156 and 180 after the first dose in the original trial
Type-specific infection and/or lesion endpoints associated with other high-risk HPV types, including HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68
Periodo de tiempo: At months 156 and 180 after the first dose in the original trial

6-month persistent infection and grade 2 or worse cervical intraepithelial

At months 156 and 180 after the first dose in the original trial
Type-specific seropositivity rates for HPV-16 and HPV-18 antibodies
Periodo de tiempo: At months 156 and 180 after the first dose in the original trial

Percentage of participants seropositive for HPV-16 and HPV-18 antibodies

At months 156 and 180 after the first dose in the original trial
Type-specific HPV-16 and HPV-18 antibody levels
Periodo de tiempo: At months 156 and 180 after the first dose in the original trial

Serum antibody titers against HPV-16 and HPV-18

At months 156 and 180 after the first dose in the original trial

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
incident HPV-16 and/or HPV-18 infection
Periodo de tiempo: At months 156 and 180 after the first dose in the original trial

Newly detected HPV-16 and/or HPV-18 DNA positivity

At months 156 and 180 after the first dose in the original trial

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Silla de estudio: Jun Zhang, Xiamen University
  • Investigador principal: Ting Wu, Xiamen University

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de enero de 2027

Finalización primaria (Estimado)

31 de diciembre de 2029

Finalización del estudio (Estimado)

31 de diciembre de 2029

Fechas de registro del estudio

Enviado por primera vez

14 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

14 de noviembre de 2026

Publicado por primera vez (Actual)

19 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

14 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Descripción del plan IPD

Proposals should be sent to the Principal Investigator. Proposals will be reviewed and approved by the study team.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir